The Art Of Creative Deal Making
This article was originally published in Scrip
A challenging entry to 2016, with biotech's stock fallout, IPO struggles and the pharma industry's instability because of increasing global pricing woes and shifting business models, has put a spotlight on the industry to be more creative. As such, the topic of how to get adventurous in deal making shaped a lively debate at the recent European Life Science CEO forum in Zurich, Switzerland.
Register for our free email digests: